Medical Disorders
Resources
Basic InformationLookupsLatest News
Knee or Hip Replacements Cut People's Risk for Falls: StudyWhat Will It Take for People to Embrace a COVID Vaccine?Kidney Trouble Greatly Raises Odds for Fatal COVID-19More Evidence Masks Slow COVID's SpreadDangerous COVID-19 Syndrome First Seen in Kids Also Strikes AdultsFading Sense of Smell Could Signal Higher Death Risk in Older AdultsHospitals Straining Under Weight of Surging COVID Case CountsU.S. Daily COVID-19 Case Count Sets New Record for the PandemicAn Unexpected Finding on What Might Drive Joint DiseaseU.S. Daily COVID Case Count Nears Record for PandemicCould Common Asthma Meds Weaken Bones?Mask Use by Americans Now Tops 90%, Poll FindsCOVID-19 More Common in Pregnant Hispanics Than Other Moms-to-Be: StudyMore Than Half of Americans Know Someone Infected or Ill With COVID: PollCDC Broadens Definition of 'Close Contact' in Tracing COVID InfectionsAHA News: The Mummies' Message: Take Steps Against Heart DiseasePancreas Cells That Drive Type 1 Diabetes Appear in Healthy People, TooOne Big Reason Women May Be Less Prone to COVID-19New Wave of COVID Infections Taking Hold in AmericaSmog Tied to Raised Risk for Parkinson's, Alzheimer's DiseaseWhat Will Convince Americans to Get a COVID-19 Vaccine?Curbing COVID Brought Unexpected Benefit for Asthma Patients1 in 3 Americans With Arthritis Say Pain, Symptoms PersistCDC Recommends Face Masks in All Public Transportation SettingsIn Medieval Times, Plagues 'Sped Up' With Each New OutbreakWhat You Need to Know About Your Colon Cancer RiskNewer Rheumatoid Arthritis Drug May Help Ease Tough-to-Treat CasesCelebrate Autumn Traditions Without Raising Your COVID RiskNew Drug Could Extend Life for People With ALSHeart Defects Don't Increase Risk of Severe COVID-19America Sees Daily COVID Cases Pass 60,000 Once AgainCOVID Scored Big at 'Superspreader' Hockey GameAHA News: Belly Fat May Signal Early Heart Issues for Mexican AmericansFDA Approves First Ebola Virus TreatmentAmericans Might Need to Pass on Thanksgiving Gatherings: FauciAHA News: Flu and COVID-19 Are Bad Enough, But They Also Can Raise Stroke RiskNewborns of Moms With COVID-19 Face Little Infection Risk: StudyCOVID Cases Climbing in 36 StatesBedside COVID-19 Test Faster Than Standard PCR TestNIH Launches Trial of Antibody Drugs Against COVID-19Long-Lasting Immunity Seems to Follow Serious COVID CasesAHA News: How Much Do You Know About Thrombosis? Probably Not EnoughCOVID-19 Taking Huge Toll in Excess U.S. DeathsSecond COVID Vaccine Trial Paused for Unexplained IllnessBlacks, Asians More Likely Than Whites to Have Severe COVIDUpper Midwest Sees COVID-19 Surge as Northeast Worries About a Second WaveRemdesivir Speeds Recovery for COVID PatientsAnimal Study Points to Heating Coil Behind Serious Vaping InjuriesAHA News: Strokes and Heart Attacks Increase When Flu-Like Illnesses RiseZika Epidemic Was More Widespread Than Thought: Study
Questions and AnswersVideosLinksBook Reviews
Related Topics

Cancer
Men's Health
Women's Health

New Drug Could Extend Life for People With ALS

HealthDay News
by -- Robert Preidt
Updated: Oct 16th 2020

new article illustration

FRIDAY, Oct. 16, 2020 (HealthDay News) -- An experimental drug combination lengthens survival for patients with amyotrophic lateral sclerosis (ALS), new research shows.

A previous clinical trial found that the two-drug combo -- called AMX0035 -- slowed progression of the neurodegenerative disease over six months.

The new clinical trial of 137 patients with the disease, also known as Lou Gehrig's disease, found that those who took AMX0035 lived a median of 6.5 months longer than those who received a placebo. Median means half lived longer, half for less time.

The study, published Oct. 16 in the journal Muscle & Nerve, was conducted by researchers at Massachusetts General Hospital in Boston and Amylyx Pharmaceuticals, Inc., which makes the drug.

According to The New York Times, the drug combination was dreamed up by two Brown University students seven years ago. It combines an existing supplement and a medication for a pediatric urea disorder.

There is no cure for ALS, in which increasing damage to brain and nerve cells in the spinal cord results in a progressive loss of one's ability to move, speak, eat and even breathe.

AMX0035 is designed to reduce the death and dysfunction of motor neurons, according to the new report.

Findings published last month in the New England Journal of Medicine reported that the drug slowed progression of ALS paralysis by about 25% more than a placebo, according to the Times.

The latest results "provide substantial evidence supporting the role of AMX0035 for the treatment of ALS," said study leader Dr. Sabrina Paganoni, an investigator at the Healey and AMG Center for ALS at Mass General. "Next steps will depend on ongoing discussions with regulatory agencies," she said in a hospital news release.

Senior author Dr. Merit Cudkowicz, director of the Center for ALS, described the study as groundbreaking.

"This is one of the first studies to show effect on both function and survival," she said. "We are hopeful that this is just the beginning of many new treatments for ALS."

Both researchers are on the faculty at Harvard Medical School. Paganoni is an assistant professor of physical medicine and rehabilitation and Cudkowicz is chief of neurology.

More information

The ALS Association has more on amyotrophic lateral sclerosis.




Facebook

Amazon Smile

 

Children and Adult services are available now with no wait time.  

Please contact HBH at 860-548-0101, option 2.

 


powered by centersite dot net